Critical roles of SRC-3 in the development and progression of breast cancer, rendering it a prospective clinical target
| dc.authorid | 0000-0002-4337-9327 | en_US |
| dc.authorid | 0000-0003-0172-6957 | en_US |
| dc.contributor.author | Varışli, Lokman | |
| dc.contributor.author | Dancik, Garrett M. | |
| dc.contributor.author | Tolan, Veysel | |
| dc.contributor.author | Vlahopoulos, Spiros | |
| dc.date.accessioned | 2023-11-27T06:35:01Z | |
| dc.date.available | 2023-11-27T06:35:01Z | |
| dc.date.issued | 31.10.2023 | en_US |
| dc.department | Dicle Üniversitesi, Fen Fakültesi, Moleküler Biyoloji ve Genetik Bölümü | en_US |
| dc.description.abstract | Breast cancer (BCa) is the most frequently diagnosed malignant tumor in women and is also one of the leading causes of cancer-related death. Most breast tumors are hormone-dependent and estrogen signaling plays a critical role in promoting the survival and malignant behaviors of these cells. Estrogen signaling involves ligand-activated cytoplasmic estrogen receptors that translocate to the nucleus with various co-regulators, such as steroid receptor co-activator (SRC) family members, and bind to the promoters of target genes and regulate their expression. SRC-3 is a member of this family that interacts with, and enhances, the transcriptional activity of the ligand activated estrogen receptor. Although SRC-3 has important roles in normal homeostasis and developmental processes, it has been shown to be amplified and overexpressed in breast cancer and to promote malignancy. The malignancy-promoting potential of SRC-3 is diverse and involves both promoting malignant behavior of tumor cells and creating a tumor microenvironment that has an immunosuppressive phenotype. SRC-3 also inhibits the recruitment of tumor-infiltrating lymphocytes with effector function and promotes stemness. Furthermore, SRC-3 is also involved in the development of resistance to hormone therapy and immunotherapy during breast cancer treatment. The versatility of SRC-3 in promoting breast cancer malignancy in this way makes it a good target, and methodical targeting of SRC-3 probably will be important for the success of breast cancer treatment. | en_US |
| dc.identifier.citation | Varışli L., Dancik G.M., Tolan V., Vlahopoulos S. (2023). Critical roles of SRC-3 in the development and progression of breast cancer, rendering it a prospective clinical target. Cancers (Basel). 15(21), 5242. doi: 10.3390/cancers15215242 | en_US |
| dc.identifier.doi | 10.3390/cancers15215242 | |
| dc.identifier.issn | 2072-6694 | |
| dc.identifier.issue | 21 | en_US |
| dc.identifier.pmid | 37958417 | |
| dc.identifier.scopus | 2-s2.0-85176600437 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.startpage | 5242 | en_US |
| dc.identifier.uri | https://www.mdpi.com/2072-6694/15/21/5242 | |
| dc.identifier.uri | https://hdl.handle.net/11468/13050 | |
| dc.identifier.volume | 15 | en_US |
| dc.identifier.wos | WOS:001100327100001 | |
| dc.identifier.wosquality | N/A | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.institutionauthor | Varışli, Lokman | |
| dc.institutionauthor | Tolan, Veysel | |
| dc.language.iso | en | en_US |
| dc.publisher | MDPI | en_US |
| dc.relation.ispartof | Cancers (Basel) | |
| dc.relation.publicationcategory | Makale - Uluslararası - Editör Denetimli Dergi | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | SRC-3 | en_US |
| dc.subject | Breast cancer | en_US |
| dc.subject | Estrogen signaling | en_US |
| dc.subject | Tumor infiltrating cells | en_US |
| dc.subject | Tumor microenvironment | en_US |
| dc.title | Critical roles of SRC-3 in the development and progression of breast cancer, rendering it a prospective clinical target | en_US |
| dc.title | Critical roles of SRC-3 in the development and progression of breast cancer, rendering it a prospective clinical target | |
| dc.type | Article | en_US |
